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Peer review unLetter to the EditorA journey through narcolepsy diagnosis: From ICSD 1
to ICSD 3Narcolepsy is a term that comes from the French narcolepsie,
coined in the 19th century by the French physician Gélineau
from the combined form of the Greek words narke (“numb-
ness”, “stupor”) and lepsis (“an attack”, “seizure”). Since its
description, narcolepsy has gained increased attention, being
a sleep disorder that presents a great impact upon an
individual's life and that leads to an important daytime
impairment.
Reﬂecting concern on the consequences of this disorder,
drivers with narcolepsy in United Kingdom, for instance, are
required to inform authorities of their condition and must
have 3–6 months of satisfactory control of symptoms in order
to get licensed. Prevalence may vary from place to place, but
studies made in North America, Western Europe and Asia
show that, on average, 1 in every 3000 people have narcolepsy
[1]. Interestingly, this disorder is more common in men and its
onset occurs typically in adolescence, from 15 to 30 years [1].
Despite of researchers' efforts in understanding its patho-
physiology and ﬁnding objective measures for this disease,
some aspects of narcolepsy remain a mystery because it most
likely represents a heterogeneous disorder. However, some
complaints are sine qua non as diagnostic criteria for narco-
lepsy. Since the 1st edition of the International Classiﬁcation
of Sleep Disorders (ICSD 1 revised, 2001) [2], excessive day-
time sleepiness is presented as the ﬁrst diagnostic criteria for
narcolepsy, associated with irrepressible need to sleep, or
sudden muscle weaknesses, and recurrent daytime lapses
into sleep occurring almost daily for at least 3 months. Of
note, these criteria were maintained in the 2nd edition of the
ICSD, updated in 2005 [3], and are still part of the current
diagnosis of narcolepsy described on the 3rd edition of the
ICSD, updated in the present year [4]. In addition, the
essential associated features of narcolepsy: sleep paralysis,
hypnagogic hallucinations, automatic behaviors and dis-
rupted major sleep episode also remain unchanged.
Although some similarities can be found across the ICSD
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der responsibility of Brazilian Association of Sleep.changes occurred in this ﬁeld, especially because of advances
in understanding the pathophysiology of this disease. The 1st
revised edition of the ICSD [2] reports a single type or narcolepsy,
described as a disorder of unknown etiology, with lack of
information regarding the pathology and the familial pattern of
the disorder. The ICSD 2, already mention 4 subtypes of
narcolepsy, referred in the 5th and last edition of the Diagnostic
and Statistical Manual of Mental Disorders (DSM-V, 2013) [5]:
narcolepsy with cataplexy; narcolepsy without cataplexy; narco-
lepsy due to medical condition; unspeciﬁed narcolepsy [3]. From
this description, the cataplexic property of narcolepsy started to
be seen as a differential pattern of the disease, being more
speciﬁcally related to its genetic speciﬁcities.
At the genetic level, since ICSD 1 narcolepsy is closely
associated with the human leukocyte antigen (HLA) gene,
with the HLA DBQ1n0602 allele already cited as a potential
speciﬁc HLA marker associated with narcolepsy [2]. On the
2nd edition of ICSD, the familial pattern of narcolepsy is more
deeply speciﬁed, with the presence of the HLA DBQ1n0602
subtype being more speciﬁc to narcolepsy, and restricted to
narcolepsy with cataplexy. In the pathophysiological level,
cataplexic narcolepsy is described as a disorder associated
with the loss of approximately 50,000 to 100,000 hypothala-
mic neurons containing the neuropeptide hypocretin
(orexin). Thus, measuring cerebrospinal ﬂuid (CSF) levels of
hypocretin-1, with ﬁndings of hypocretin-1 levels r110 pg/
mL or ⅓ of mean control values, is suggested as an alternative
diagnostic criterion of narcolepsy with cataplexy in ICSD 2 [3].
However, it is only on the 3rd and more recent edition of the
ICSD that the objective measure of CSF hypocretin levels is
actually included as a diagnostic criteria of narcolepsy under
the statement that it has now been ﬁrmly established that
narcolepsy with cataplexy is caused by a deﬁciency in hypo-
cretin signaling, most likely due to a selective loss of hypotha-
lamic hypocretin producing neurons [4]. Thus, cataplexic
narcolepsy becomes essentially deﬁned as a hypocretin deﬁ-
ciency syndrome, which is reﬂected in the need for objectiveng by Elsevier B.V. This is an open access article under the CC BY-
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3 describes 2 types of narcolepsy: type 1, with cataplexy and 2
or more sleep onset REM periods (SOREMs) and sleep latency of
r8min on a multiple sleep latency test (MSLT) and/or CSF
hypocretin-1 concentration of r110 pg/mL or o⅓ of mean
control values; type 2, with absence of cataplexy, CSF
hypocretin-1 concentration not measured or 4110 pg/mL or
4⅓ of mean control values and the hypersomnolence and/or
MSLT ﬁndings not better explained by other causes. Of note,
each sort brings the speciﬁc description of type 1 or 2 narco-
lepsy due to medical conditions [4].
In conclusion, over the years new discoveries are being
made to elucidate the pathophysiology of this disorder and
medical practice is changing and beneﬁting from it. What was
once seen as a devil's work and had no apparent explana-
tions is now getting closer to be under the domain of
medicine. Although the understanding of the mechanisms
underlying narcolepsy has increasingly moved forward, driv-
ing important changes in its diagnosis, much remains to be
uncovered about this disorder. Narcolepsy is a condition with
great impact on the quality of life of patients and may
represent a risk in modern society, in which more and more
attention are demanded in order to deal with technology and
new information sources. Thus, studying narcolepsy and its
related features is of great interest not only for the individual
suffering with it, but for the society as a whole.Conﬂict of interest
All authors have no conﬂict of interest.Acknowledgments
Our studies are supported by Associação Fundo de Incentivo
à Pesquisa (AFIP) and Fundação de Amparo à Pesquisa do
Estado de São Paulo (FAPESP). ST is recipient of a fellowshipnCorrespondence to: Rua Napoleão de Barros, 925, Vila Clemen
fax: þ55 11 5572 5092.from Conselho Nacional de Desenvolvimento Cientíﬁco e
Tecnológico (CNPq).
r e f e r e n c e s
[1] Silber MH, Krahn LE, Olson EJ, Pankratz VS. The epidemiology
of narcolepsy in Olmsted County, Minnesota: A population-
based study. Sleep 2002;25:197–202.
[2] American Academy of Sleep Medicine. In: International
classification of sleep disorders, revised: Diagnostic and
coding manual. Chicago, Illinois: American Academy of Sleep
Medicine; 2001.
[3] American Academy of Sleep Medicine. International
classification of sleep disorders. 2nd ed.: Diagnostic and
coding manual. Chicago, Illinois: American Academy of Sleep
Medicine; 2005.
[4] American Academy of Sleep Medicine. International
classification of sleep disorders. 3rd ed.: Diagnostic and
coding manual. Chicago, Illinois: American Academy of Sleep
Medicine; 2014.
[5] American Psychiatric Association. Diagnostic and statistical
manual of mental disorders, 5th ed. Arlington, VA: American
Psychiatric Association; 2013.Laís F. Berro
Departamento de Psicobiologia, Universidade Federal de São Paulo
(UNIFESP), São Paulo, BrazilSergio B. Tuﬁk
Medical School, Universidade de São Paulo (USP), São Paulo, BrazilSergio Tuﬁkn
Departamento de Psicobiologia, Universidade Federal de São Paulo
(UNIFESP), São Paulo, Brazil
E-mail addresses: sergio.tuﬁk@unifesp.br, tuﬁksb@gmail.com
15 July 2014; accepted 16 July 2014tino – SP 04024-002, São Paulo, Brazil. Tel.: þ55 11 2149 0155;
